July 2018—CARB-X has awarded Specific Diagnostics up to $1.7 million to support the development of the company’s antibiotic susceptibility testing system. Up to $1.7 million more could be awarded based on achievement of project milestones. Specific’s AST instrument determines phenotypic antibiotic susceptibility within hours of blood infection.
“Specific Diagnostics’ project is an example of cutting-edge technology that could potentially speed up and change the way life-threatening infections are diagnosed and treated,” Kevin Outterson, executive director of CARB-X, said in a press release.
CARB-X, which stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, is a public-private partnership established in 2016 that provides financial and scientific support to accelerate drug-resistant bacterial infection research projects through the early stages of product development
Specific Diagnostics, 650-938-2030